MF Researcher Database

Researcher Database

Advance

Horiike Atsushi

■FacultyMedical Oncology
■PositionAssociate Professor
Last Updated :2025/04/01

Researcher

基本情報

Profile and Settings

  • 氏名

    Horiike Atsushi

Affiliation

  • Medical Oncology, Associate Professor

Location

  • University Hospital

Degree

  • Doctor of Medical Science, Toho University, Mar. 2019

Achievements

Published Papers

  • Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study., Kashimura Saeko;Sato Miki;Inagaki Takahito;Kin Masaoki;Manabe Ryo;Kusumoto Sojiro;Horiike Atsushi;Tsunoda Takuya;Kogo Mari, Thoracic cancer, 15(28), Aug. 2024, Peer-reviewed
  • Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study., Kashimura Saeko;Sato Miki;Inagaki Takahito;Kin Masaoki;Manabe Ryo;Kusumoto Sojiro;Horiike Atsushi;Tsunoda Takuya;Kogo Mari, Thoracic cancer, 15(28), Aug. 2024, Peer-reviewed
  • Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody., Murayama Masakazu;Hosonuma Masahiro;Kuramasu Atsuo;Kobayashi Sei;Sasaki Akiko;Baba Yuta;Narikawa Yoichiro;Toyoda Hitoshi;Isobe Junya;Funayama Eiji;Tajima Kohei;Sasaki Aya;Maruyama Yuki;Yamazaki Yoshitaka;Shida Midori;Hamada Kazuyuki;Hirasawa Yuya;Tsurui Toshiaki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Risako;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Sambe Takehiko;Tsuji Mayumi;Wada Satoshi;Kobayashi Shinichi;Shimane Toshikazu;Tsunoda Takuya;Kobayashi Hitome;Kiuchi Yuji;Yoshimura Kiyoshi, Scientific reports, 14(1), May 2024, Peer-reviewed
  • Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors., Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S., Front Immunol, 14:1260492, Sep. 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1260492
  • Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, May 2023, Peer-reviewed, DOI:10.3389/fimmu.2023.1164724
  • The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure, SUGANUMA Hiromitsu;KUSUMOTO Sojiro;MANABE Ryo;KISHINO Yasunari;ENDO Tetsuya;ANDO Koichi;ISHIDA Hiroo;HORIIKE Atsushi;TANAKA Akihiko;TAKEI Hidefumi;YAMOCHI Toshiko;TSUNODA Takuya;SAGARA Hironori, Showa Univ J Med Sci, 34(2):64 - 77, Jun. 2022, Peer-reviewed, DOI:https://doi.org/10.15369/sujms.34.64
  • 肺がんに対する薬物療法の最前線, 堀池　篤, 昭和学士会雑誌, 81(3):131 - 138, Aug. 2021, Peer-reviewed
  • The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021, Peer-reviewed
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer., Kubota Yutaro;Yoshimura Kiyoshi;Hamada Kazuyuki;Hirasawa Yuya;Shida Midori;Taniguchi Makoto;Matsui Hiroto;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Norihiro;Ohkuma Ryotaro;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, In vivo (Athens, Greece), 35(3), 2021, Peer-reviewed
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23), 2021, Peer-reviewed
  • High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer., Ohkuma Ryotaro;Yada Erica;Ishikawa Shumpei;Komura Daisuke;Kubota Yutaro;Hamada Kazuyuki;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Shida Midori;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Sasada Tetsuro;Aoki Takeshi;Murakami Masahiko;Norose Tomoko;Ohike Nobuyuki;Takimoto Masafumi;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, International journal of oncology, 58(1), Nov. 2020, Peer-reviewed
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Ando Kiyohiro;Hamada Kazuyuki;Shida Midori;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Matsui Hiroto;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Tsurutani Junji;Yoshimura Kiyoshi;Tsunoda Takuya;Kobayashi Shinichi;Wada Satoshi, Cancer immunology, immunotherapy : CII, 70(2), Aug. 2020, Peer-reviewed
  • 腎癌および尿路上皮癌患者におけるバイオマーカー探索のための腸内細菌叢の研究, 下山　英明;直江　道夫;サト　プラサド　ネパール;平松　綾;松井　祐輝;鵜木　勉;中里　武彦;押野見　和彦;森田　順;前田　佳子;冨士　幸藏;小川　良雄;角田　卓也;吉村　清, 昭和学士会雑誌, 79(4):492 - 504, Aug. 2019, Peer-reviewed

Presentations

  • 医師主導治験におけるプロジェクトマネージャーと実施施設CRCとの情報共有の試み～今後の改善に向けて～, 竹ノ下祥子、深井しのぶ、山本明子、佐野良子、山口佳耶、西澤三保子、西岡信子、日比野文代、松下知司、堀池篤, 第23回CRCと臨床試験のあり方を考える会議in岡山, 16 Sep. 2023
  • Assessment and risk control sheet facilitates management in cancer drug therapy, 本間　織重;渡邊　知映;福地本　晴美;柏崎　純子;園生　容子;我妻　志保;細沼　雅弘;久保田　祐太郎;倉増　敦朗;堀池　篤;石田　博雄;嶋田　顕;角田　卓也;梅田　恵;吉村　清, 第59回日本癌治療学会学術集会, 23 Oct. 2021, 横浜・LIVE配信・オンデマンド配信
  • 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉　裕嗣;吉村　清;堀池　篤;平澤　優弥;石黒　智之;大熊　遼太朗;久保田　祐太郎;濵田　和幸;和田　聡;鶴谷　純司;角田　卓也, 第25回日本がん免疫学会総会, 03 Jul. 2021, 和歌山
  • 体幹部定位放射線治療による肺合併症の実際, 楠本　壮二郎;岸野　康成;小林　玲;安藤　浩一;久保田　祐太郎;村上　幸三;堀池　篤;大森　亨;伊藤　芳紀;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 14 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • オンコマインDx Target Test マルチ CDx システム導入における Cancer Board での取り組み, 大熊　遼太朗;堀池　篤;楠本　壮二郎;三浦　咲子;井戸　愛;村上　幸三;遠藤　哲哉;矢持　淑子;扇谷　芳光;伊藤　芳紀;武井　秀史;相良　博典;角田　卓也, 第61回日本肺癌学会学術集会, 12 Nov. 2020, 岡山およびライブ配信・オンデマンド配信
  • PS良好PD-L1高発現NSCLCに対するPembrolizumab療法とプラチナ製剤併用＋Pembrolizumab療法の有効性の検討, 岸野　康成;楠本　壮二郎;堀池　篤;有泉　裕嗣;久保田　祐太郎;安藤　浩一;田中　明彦;大森　亨;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 12 Nov. 2020, 岡山およびライブ配信・オンデマンド配信

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.